Determination of the circulating levels of prostate-specific antigen (PSA), rather than the more invasive procedure of histological detection of prostate cancer through biopsy, is a typical surrogate biomarker used for screening [89]. This evidence concerns the gene KLK3 and prostate carcinoma.